Madrigal Pharmaceuticals (NASDAQ:MDGL) had its target price hoisted by stock analysts at Roth Capital from $82.00 to $170.00 in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s price objective suggests a potential upside of 110.45% from the company’s current price.
A number of other analysts have also recently weighed in on the stock. Evercore ISI initiated coverage on shares of Madrigal Pharmaceuticals in a report on Friday, September 22nd. They issued an “outperform” rating and a $65.00 price objective on the stock. JMP Securities increased their price objective on shares of Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the stock an “outperform” rating in a report on Friday, October 13th. Finally, HC Wainwright initiated coverage on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 29th. They issued a “buy” rating and a $54.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $135.00.
Shares of Madrigal Pharmaceuticals (MDGL) opened at $80.78 on Monday. Madrigal Pharmaceuticals has a twelve month low of $13.09 and a twelve month high of $101.00.
Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the 3rd quarter worth about $100,000. New York State Common Retirement Fund acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at about $109,000. California State Teachers Retirement System acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at about $117,000. TIAA CREF Investment Management LLC acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at about $120,000. Finally, Bank of New York Mellon Corp acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at about $179,000. 21.40% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Roth Capital Increases Madrigal Pharmaceuticals (MDGL) Price Target to $170.00” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.com-unik.info/2017/12/13/roth-capital-increases-madrigal-pharmaceuticals-mdgl-price-target-to-170-00.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
What are top analysts saying about Madrigal Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Madrigal Pharmaceuticals and related companies.